Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NYSE:GSK On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeGSKGSK$37.60+2.3%$38.80$31.72▼$44.67$74.98B0.516.15 million shs3.71 million shs7 Energy Stocks to Buy and Hold ForeverWith the proliferation of data centers and electric vehicles, the electric grid will only get more strained. Download this report to learn how energy stocks can play a role in your portfolio as the global demand for energy continues to grow.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceGSKGSK+2.20%+1.21%-2.32%+2.64%-4.51%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationGSKGSK2.5799 of 5 stars0.95.02.50.03.10.02.5Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceGSKGSK 1.88Reduce$37.38-0.59% DownsideCurrent Analyst Ratings BreakdownLatest GSK Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails6/3/2025GSKGSKBerenberg BankSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Hold(Data available from 8/8/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookGSKGSK$40.10B1.91$5.71 per share6.59$9.40 per share4.00Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateGSKGSK$3.29B$2.1617.418.091.6010.81%49.22%11.31%N/ALatest GSK EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails7/30/2025Q2 2025GSKGSK$1.12$1.23+$0.11$0.94$7.92 billion$10.64 billionCompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthGSKGSK$1.714.55%N/A79.17%N/ALatest GSK DividendsAnnouncementCompanyPeriodAmountYieldEx-Dividend DateRecord DatePayable Date7/31/2025GSKGSKquarterly$0.42064.3%8/15/20258/15/202510/9/2025(Data available from 1/1/2013 forward)Compare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioGSKGSK1.070.870.57Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipGSKGSK15.74%Insider OwnershipCompanyInsider OwnershipGSKGSK10.00%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableGSKGSK68,6292.04 billion1.84 billionOptionableGSK HeadlinesRecent News About These CompaniesGSK PLC Sponsored ADR (NYSE:GSK) Shares Sold by Arjuna Capital3 hours ago | marketbeat.comGSK to Receive $370 Million in U.S. Patent Litigation SettlementAugust 8 at 3:31 AM | wsj.comGSK secures $370 million settlement and future royalties in CureVac mRNA patent disputeAugust 8 at 3:03 AM | proactiveinvestors.co.ukGSK secures $370 million settlement and future royalties in CureVac mRNA patent disputeAugust 8 at 2:51 AM | proactiveinvestors.co.ukPrimecap Management Co. CA Increases Holdings in GSK PLC Sponsored ADR (NYSE:GSK)August 7 at 7:33 AM | marketbeat.comGSK’s Promising Study on Belimumab for Systemic Sclerosis Lung DiseaseAugust 6 at 12:36 PM | tipranks.comGSK’s RSV Vaccine Study: A Potential Game-Changer for Older AdultsAugust 5 at 12:42 PM | tipranks.comINVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of GSK plc – GSKAugust 5 at 10:00 AM | globenewswire.comGSK’s world-first gonorrhoea vaccine launched in EnglandAugust 5 at 7:36 AM | pharmaceutical-technology.comPGSK PLC Sponsored ADR (NYSE:GSK) Shares Purchased by Natixis Advisors LLCAugust 5 at 6:38 AM | marketbeat.comFederated Hermes Inc. Grows Stock Holdings in GSK PLC Sponsored ADR (NYSE:GSK)August 5 at 6:29 AM | marketbeat.comLPL Financial LLC Grows Stock Holdings in GSK PLC Sponsored ADR (NYSE:GSK)August 5 at 6:29 AM | marketbeat.comUS Bancorp DE Acquires 9,473 Shares of GSK PLC Sponsored ADR (NYSE:GSK)August 5 at 4:21 AM | marketbeat.comGSK (NYSE:GSK) Stock Rating Upgraded by Wall Street ZenAugust 5 at 2:49 AM | americanbankingnews.comNeutral GSK Pharma; target of Rs 3000: Motilal OswalAugust 4, 2025 | moneycontrol.comMackenzie Financial Corp Takes $5.97 Million Position in GSK PLC Sponsored ADR (NYSE:GSK)August 3, 2025 | marketbeat.comGSK (NYSE:GSK) Upgraded by Wall Street Zen to Buy RatingAugust 3, 2025 | marketbeat.comGSK PLC Sponsored ADR (NYSE:GSK) Stock Holdings Lowered by Mesirow Financial Investment Management Inc.August 2, 2025 | marketbeat.comArkadios Wealth Advisors Raises Stock Holdings in GSK PLC Sponsored ADR (NYSE:GSK)August 2, 2025 | marketbeat.comGSK PLC Sponsored ADR (NYSE:GSK) Declares $0.42 Quarterly DividendAugust 1, 2025 | marketbeat.comGSK Pharma on track to bring in its oncology products Jemperli and ZejulaAugust 1, 2025 | thehindubusinessline.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeGSK Company DescriptionsGSK NYSE:GSK$37.60 +0.85 (+2.30%) Closing price 08/7/2025 03:59 PM EasternExtended Trading$37.73 +0.13 (+0.36%) As of 09:24 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.GSK plc, together with its subsidiaries, engages in the research, development, and manufacture of vaccines, and specialty and general medicines to prevent and treat disease in the United Kingdom, the United States, and internationally. It operates through two segments, Commercial Operations and Total R&D. The company offers shingles, meningitis, respiratory syncytial virus, flu, polio, influenza, and pandemic vaccines. It also provides medicines for HIV, oncology, respiratory/immunology, and other specialty medicine products, as well as inhaled medicines for asthma and chronic obstructive pulmonary disease, and antibiotics for infections. It has a collaboration agreement with CureVac to develop mRNA-based influenza vaccines, and with Wave Life Sciences and Elsie Biotechnologies, Inc for oligonucleotide platform development. The company was formerly known as GlaxoSmithKline plc and changed its name to GSK plc in May 2022. GSK plc was founded in 1715 and is headquartered in Brentford, the United Kingdom. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas D-Wave Delivers Growth Shock—Investors Eye Quantum Future Constellation Energy’s Earnings Beat Signals a New Era AppLovin’s Q2 Miss Spooks Market, But Wall Street Doubles Down Realty Income Rallies Post-Earnings Miss—Here’s What Drove It Don't Mix the Signal for Noise in Super Micro Computer's Earnings Microsoft Stock Gains as Analysts Boost Price Targets Joby Deal Gives Blade New Direction, But Stock Lacks Lift Uber Technologies Is Driving Cash Flow: Ride It Higher for Life Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
